|
Mean percentage of hours of optimal sedation (intent to treat population) |
||||
| Remifentanil (n = 77) |
Fentanyl (n = 75) |
P |
||
|
|
||||
| Maintenance phase |
||||
| Median duration (h; range) |
13.7 (2.7–73.0) |
14.2 (0.3–73.3) |
NT |
|
| Mean (range) % of hours of optimal sedation |
88.3 (0.0–100.0) |
89.3 (32.5–100.0) |
NS* |
|
| Ratio of between-patient variability (fentanyl versus remifentanil) |
1.09 |
NS† |
||
| Maintenance phase (excluding the patient in the remifentanil group who failed to achieve an SAS score of 4) |
||||
| Mean (range) % of hours of optimal sedation |
89.5 (45.2–100.0) |
89.3 (32.5–100.0) |
NS* |
|
| Ratio of between-patient variability (fentanyl versus remifentanil) |
1.84 |
0.009† |
||
| Extubation phase |
||||
| Mean (range) % of hours of optimal sedation |
87.7 (0.0–100.0) |
95.5 (40.0–100.0) |
NT |
|
| Postextubation phase |
||||
| Mean (range) % of hours of optimal sedation |
92.3 (0.0–100.0) |
95.7 (32.3–100.0) |
NT |
|
| Post-treatment period |
||||
| Mean (range) % of hours of optimal sedation |
92.6 (0.0–100.0) |
91.6 (0.0–100.0) |
NT |
|
|
*Unpaired t-test on arcsine square root transformed data; †F test. NS, not significant; NT, not tested; SAS, Sedation–Agitation Scale. | ||||
Muellejans et al. Critical Care 2004 8:R1 doi:10.1186/cc2398 |
||||